406 related articles for article (PubMed ID: 17211093)
1. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
2. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
Sowa H; Hamaya E; Yamamoto T
Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
[TBL] [Abstract][Full Text] [Related]
3. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
5. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
Endo I; Matsumoto T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
9. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
[TBL] [Abstract][Full Text] [Related]
13. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
14. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
Yamamoto T; Hamaya E; Sowa H
Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
[TBL] [Abstract][Full Text] [Related]
15. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
16. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
Ishizuya T
Clin Calcium; 2011 Jan; 21(1):17-24. PubMed ID: 21187590
[TBL] [Abstract][Full Text] [Related]
18. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
Nakamura Y
Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
Miyauchi A
Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
[TBL] [Abstract][Full Text] [Related]
20. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
Saito M; Marumo K
Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]